CLINICAL RESEARCH: CORONARY ARTERY DISEASE
Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive ProteinA Meta-Analysis
Scott Kinlay, MBBS, PhD, FRACP, FACC*,1
Veteran’s Affairs Boston Healthcare System, West Roxbury Campus, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts.
Manuscript received January 19, 2006;
revised manuscript received December 19, 2006,
accepted January 3, 2007.
* Reprint requests and correspondence: Dr. Scott Kinlay, Cardiovascular Division, VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, Massachusetts 02132. (Email: skinlay{at}partners.org).
Objectives: This study sought to assess the contribution of low-density lipoprotein (LDL)–dependent and LDL–independent effects of LDL-lowering therapies to changes in C-reactive protein (CRP) in healthy or stable subjects.
Background: Correlations of change in LDL and CRP in individuals are lowered by their measurement variability. By using average changes in LDL and CRP in study groups, meta-analysis reduces this variability to better assess their correlation.
Methods: A systematic search for randomized placebo-controlled trials reporting change in LDL and CRP with LDL-lowering interventions retrieved 23 studies with 57 groups treated with a variety of statins, nonstatin drugs, or other regimens. Meta-analysis techniques assessed the relationships between average mean differences (placebo – treatment) in change in CRP and LDL.
Results: The overall reduction in CRP was 28% (95% confidence interval 26% to 30%). Significantly greater CRP reduction occurred in statin and statin-ezetimibe interventions, interventions using 80 mg/day of statins, and with greater LDL lowering. Meta-regression analysis showed a strong correlation between the change in LDL and CRP (r = 0.80, p < 0.001). Statin therapies had no significant effect on CRP after adjusting for the change in LDL. In a multivariate model applied to a range of LDL reduction typically seen with statins (20% to 60%), 89% to 98% of CRP change was related to LDL lowering and 2% to 11% was related to non-LDL effects of statins.
Conclusions: In clinical practice, most of the anti-inflammatory effect of LDL-lowering therapies is related to the magnitude of change in LDL. The potential non-LDL effects of statins on inflammation are much smaller in magnitude.
|
Abbreviations and Acronyms
| | CRP = C-reactive protein | | LDL = low-density lipoprotein | | RCT = randomized controlled trial |
|
Related Article
-
Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?
- E. Murat Tuzcu and Stephen J. Nicholls
J. Am. Coll. Cardiol. 2007 49: 2010-2012.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. Danesh and M. B. Pepys
C-Reactive Protein and Coronary Disease: Is There a Causal Link?
Circulation,
November 24, 2009;
120(21):
2036 - 2039.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Morrissey, G. A. Diamond, and S. Kaul
Statins in Acute Coronary Syndromes: Do the Guideline Recommendations Match the Evidence?
J. Am. Coll. Cardiol.,
October 6, 2009;
54(15):
1425 - 1433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M D de Kruif, M Limper, H R Hansen, J de Ruiter, C A Spek, E C M van Gorp, I J ten Berge, A T Rowshani, H ten Cate, and E W Meesters
Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus
Ann Rheum Dis,
October 1, 2009;
68(10):
1654 - 1654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Zhang, A. Matsunaga, D. L. Rainwater, S.-i. Miura, K. Noda, H. Nishikawa, Y. Uehara, K. Shirai, M. Ogawa, and K. Saku
Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study
J. Lipid Res.,
September 1, 2009;
50(9):
1832 - 1841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Al Badarin, I. J. Kullo, S. L. Kopecky, and R. J. Thomas
Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?
Mayo Clin. Proc.,
April 1, 2009;
84(4):
353 - 361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Hingorani, T. Shah, J. P. Casas, S. E. Humphries, and P. J. Talmud
C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?
Clin. Chem.,
February 1, 2009;
55(2):
239 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. B. Grammer, W. Marz, W. Renner, B. O. Bohm, and M. M. Hoffmann
C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study
Eur. Heart J.,
January 2, 2009;
30(2):
170 - 182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Settergren, F. Bohm, L. Ryden, and J. Pernow
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Eur. Heart J.,
July 2, 2008;
29(14):
1753 - 1760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kinlay
Vascular form and function: two mechanisms for cardiovascular prevention
Eur. Heart J.,
July 2, 2008;
29(14):
1711 - 1713.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ben-Yehuda
High-Sensitivity C-Reactive Protein in Every Chart?: The Use of Biomarkers in Individual Patients
J. Am. Coll. Cardiol.,
May 29, 2007;
49(21):
2139 - 2141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Tuzcu and S. J. Nicholls
Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?
J. Am. Coll. Cardiol.,
May 22, 2007;
49(20):
2010 - 2012.
[Full Text]
[PDF]
|
|
|
|
